title: [Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
abstract: We retrospectively investigated the efficacy and toxicity of lapatinib plus capecitabine in 45 HER2-positive breast cancer patients. The median number of treatment courses was 6(1-22). Brain metastasis developed in 18 cases(40%), and 19 cases(42.2%)had received previous capecitabine treatment for metastatic breast cancer. The objective response rate(ORR=CR+PR)was 22.2%(10/45), and clinical benefit rate(CR+PR+long SD=24w)was 46.7%(21/45).The median time to progression(TTP)was 24.9 weeks(95% CI: 15.2 -34.6 ), and the median overall survival(OS)was 78.1 weeks(95% CI: 55.7 -100.5)in all 45 cases. The median TTP was significantly longer in patients who had not received capecitabine previously(30 vs 16 weeks, 95% CI: 16.3 -43.7, p=0.0051 ). There was no statistical difference in median OS associated with previous capecitabine exposure(42.7 weeks, 95% CI: 21.4 -64, p=0.057 ). The median TTP was significantly longer in patients who received less than 2 treatment regimens with trastuzumab for MBC rather than 3 regimens more(27.3 vs 16 weeks, p=0.0257 ), but there was no statistical difference in median OS(81 vs 40.9 weeks, p=0.26 ). Lapatinib in combination with capecitabine is likely more useful in patients who are naive to capecitabine, who received less than two regimens for metastatic breast cancer.
authors.affiliation: Dept. of Breast and Endocrine Surgery, Kanagawa Cancer Center.
authors.forename: Akihiko
authors.initials: A
authors.lastname: Chiba
authors.forename: Satoru
authors.initials: S
authors.lastname: Shimizu
authors.forename: Akira
authors.initials: A
authors.lastname: Yoshida
authors.forename: Masaaki
authors.initials: M
authors.lastname: Inaba
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Matsuura
authors.forename: Hiroyo
authors.initials: H
authors.lastname: Ino
authors.forename: Nobuyasu
authors.initials: N
authors.lastname: Suganuma
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Inari
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamanaka
authors.forename: Kanako
authors.initials: K
authors.lastname: Kuroda
authors.forename: Tomoe
authors.initials: T
authors.lastname: Mukaibashi
authors.forename: Ayumi
authors.initials: A
authors.lastname: Matsuo
authors.forename: Izumi
authors.initials: I
authors.lastname: Kojima
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D000077341:Lapatinib; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D012189:Retrospective Studies
chemical_list: D000069287:Capecitabine; D003841:Deoxycytidine; D005472:Fluorouracil; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases